Ovid Therapeutics (OVID) Long-Term Investments (2021 - 2026)

Ovid Therapeutics (OVID) has reported Long-Term Investments for 6 consecutive years, with $52.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Investments rose 151.34% year-over-year to $52.6 million; the trailing twelve-month figure through Jun 2026 stood at $52.6 million (up 151.34% YoY), and the FY2025 full-year result was $42.0 million, up 100.06% from the prior year.
• Long-Term Investments climbed to $52.6 million in Q2 2026 per OVID's latest filing, from $42.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $52.6 million in Q2 2026 and bottomed at $2.2 million in Q2 2022.
• Historically, Long-Term Investments has averaged $19.8 million across 5 years, with a median of $20.9 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Long-Term Investments surged 639.07% in 2023, then fell 5.06% in 2025.
• Over 5 years, Long-Term Investments stood at $5.6 million in 2022, then soared by 213.49% to $17.6 million in 2023, then increased by 18.99% to $21.0 million in 2024, then soared by 100.06% to $42.0 million in 2025, then rose by 25.24% to $52.6 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $52.6 million, $42.0 million, and $42.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.